Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME and Absolute Bioavailability of Sevasemten in Healthy Men
NCT05730842Phase 1Completed
- Start
- Jan 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sevasemten in Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD) (2 arms). Primary endpoints: Mass balance of EDG-5506 as measured by the total radioactivity recovered in urine up to 37 days, Mass balance of EDG-5506 as measured by the total radioactivity recovered in feces up to 37 days and 3 more. Started Jan 2023; status: completed.
02
Drugs
sevasemten
03
Conditions
Becker muscular dystrophy (BMD)Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT05730842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05730842.